美国泛自闭症障碍治疗市场规模、份额和趋势分析报告：按治疗类型、应用、分销管道和细分市场预测（2025-2033 年）

美国泛自闭症障碍治疗市场摘要

2024年美国泛自闭症障碍治疗市场规模估计为8.2784亿美元，预计2033年将达到14.316亿美元。

预计从 2025 年到 2033 年，该市场将以 6.30% 的复合年增长率成长。诊断率的提高和治疗服务的普及正在推动美国泛自闭症障碍(ASD) 治疗市场的成长。

看护者、小儿科和教育工作者对自闭症谱系障碍的认识不断提高，推动了早期筛检的增加和及时转诊至专科护理。行为疗法、药物疗法和数位平台等治疗机构正在扩大服务范围，以满足日益增长的需求。不断发展的诊断技术持续支持更精准、更个人化的治疗方案，有助于整体治疗效果的提升。例如，美国疾病管制与预防中心（CDC）在2025年5月报告称，每31名8岁儿童中就有1名（3.2%）被诊断患有泛自闭症障碍，并指出该疾病在不同种族、民族和社会经济群体中均有发生。该机构还指出，自闭症在男孩中的发生率是女孩的三倍多，2009 年至 2017 年间，六分之一（17%）的 3 至 17 岁儿童被诊断患有发育障碍（包括泛自闭症障碍），2022 年的患病率为每 1000 名儿童 32.2 人（31 人中 11 人）。

在美国，药物研发仍然是泛自闭症障碍治疗产业的关键驱动力。各公司正致力于研发针对易怒、过动和行为失调等症状的治疗方法。强大的后期开发平臺有望扩大儿童和成人的治疗覆盖范围。将数位行为疗法融入临床路径，提高了治疗的一致性、扩充性和可近性，尤其对需要远距介入的家庭而言更是如此。将结构化行为疗法与药物治疗结合的实证治疗方法，能够改善患者的功能和社会功能。这些不断发展的护理模式正在推动不同患者群体接受治疗。

对研究、数据驱动技术和跨学科护理的投资持续推动美国市场的发展。先进的分析工具正在加深我们对神经生物学机制的理解，并加速发现新的治疗标靶。美国学术机构、临床网络和产业伙伴之间的紧密合作正在提高临床试验的效率和转化研究的成功率。例如，2025年5月，美国疾病管制与预防中心（CDC）重申，泛自闭症障碍的诊断取决于看护者的发展史以及基于DSM-5标准的行为评估。这些标准包括三个严重程度等级：1级（需要支援）、2级（需要大量支援）和3级（需要非常大量的支援）。整合医疗保健、行为疗法、教育和数位科技的跨学科照护框架的日益普及，正在帮助美国泛自闭症障碍的治疗环境朝着更全面和永续的未来迈进。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国泛自闭症障碍治疗市场变数、趋势与范围

• 市场谱系展望
• 市场动态
• 商业环境分析
  • 产业分析—波特五力分析
  • PESTLE分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章美国泛自闭症障碍治疗市场：按治疗类型分類的业务分析

• 按治疗类型分類的市场份额（2024 年和 2033 年）
• 按治疗类型分類的市场规模、预测和趋势分析（2021-2033 年）
• 抗精神病药物
• 选择性血清素再回收抑制剂
• 兴奋剂
• 安眠药
• 其他的

第五章美国泛自闭症障碍治疗市场：按应用领域分類的业务分析

• 按应用领域分類的市场份额（2024 年和 2033 年）
• 按应用领域分類的市场规模、预测和趋势分析（2021-2033 年）
• 泛自闭症障碍
• 亚斯伯格症候群
• 广泛性发展障碍
• 其他的

第六章美国泛自闭症障碍治疗市场：按通路分類的业务分析

• 按分销管道分類的市场份额（2024 年和 2033 年）
• 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
• 医院药房
• 零售药房
• 网路药房

第七章 竞争情势

• 参与企业概况
• 企业市场分析
• 公司分类
• 策略规划
• 公司简介/列表
  • Johnson &Johnson（Janssen）
  • Roche（F. Hoffmann-La Roche）
  • Otsuka Pharmaceutical Co., Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Eli Lilly &Company
  • Curemark LLC
  • Yamo Pharmaceuticals
  • PaxMedica
  • Merck &Co., Inc.

U.S. Autism Spectrum Disorder Treatment Market Summary

The U.S. autism spectrum disorder treatment market size was estimated at USD 827.84 million in 2024 and is projected to reach USD 1,431.60 million by 2033, growing at a CAGR of 6.30% from 2025 to 2033. The increasing diagnosis rates and wider access to therapeutic services drive the growth of the Autism Spectrum Disorder (ASD) treatment market in the U.S.

Growing awareness among caregivers, pediatricians, and educators has led to increased early screening and expedited referrals to specialized care. Treatment providers across behavioral therapy, pharmacologic care, and digital platforms are broadening their service footprint to meet the rising demand. Diagnostic refinement continues to support more precise and individualized care pathways, thereby improving overall treatment outcomes. For instance, in May 2025, the Centers for Disease Control and Prevention reported that 1 in 31 children aged 8 years (3.2%) had been identified with autism spectrum disorder, noting occurrence across all racial, ethnic, and socioeconomic groups. The agency further stated that autism was more than three times more common in boys than in girls and that 1 in 6 children aged 3-17 years (17%) had been diagnosed with a developmental disability-including autism spectrum disorder-between 2009 and 2017, with 2022 prevalence at 32.2 per 1,000 children (1 in 31).

Pharmaceutical development remains a central growth driver for the U.S. autism spectrum disorder treatment industry, as the companies focus on therapies addressing irritability, hyperactivity, and behavioral dysregulation. A robust late-stage pipeline is expected to expand treatment eligibility across both pediatric and adult populations. The integration of digital behavioral therapies into clinical pathways is enhancing consistency, scalability, and accessibility, particularly for families requiring remote interventions. Evidence-based treatment combinations, including structured behavioral programs paired with pharmacologic support, strengthen functional and social outcomes. These evolving care models are increasing the adoption of treatment across diverse patient segments.

Investment in research, data-driven technologies, and multidisciplinary care continues to shape the U.S. market's progress. Advanced analytic tools are deepening the understanding of neurobiological mechanisms, accelerating the discovery of new therapeutic targets. Strong collaboration between U.S. academic centers, clinical networks, and industry partners is enhancing trial efficiency and translational success. For instance, in May 2025, the Centers for Disease Control and Prevention reiterated that autism spectrum disorder diagnosis relies on caregiver developmental histories and behavioral assessments guided by DSM-5 criteria, which include three severity levels, namely, Level 1 requiring support, Level 2 requiring substantial support, and Level 3 requiring very substantial support. The growing use of multidisciplinary care frameworks, combining medical, behavioral, educational, and digital components, continues to reinforce a more holistic and sustainable U.S. Autism Spectrum Disorder treatment landscape.

U.S. Autism Spectrum Disorder Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. autism spectrum disorder treatment market report based on treatment type, application, and distribution channel:

• Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
• Antipsychotic Drugs
• Selective Serotonin Reuptake Inhibitors
• Stimulants
• Sleep Medications
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Autistic Disorder
• Asperger Syndrome
• Pervasive Developmental Disorder
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment Type
  • 1.2.2. Application
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Autism Spectrum Disorder Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Autism Spectrum Disorder Treatment Market: Treatment Type Business Analysis

• 4.1. Treatment Type Market Share, 2024 & 2033
• 4.2. Treatment Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
• 4.4. Antipsychotic Drugs
  • 4.4.1. Antipsychotic Drugs Market, 2021 - 2033 (USD Million)
• 4.5. Selective Serotonin Reuptake Inhibitors
  • 4.5.1. Selective Serotonin Reuptake Inhibitors Market, 2021 - 2033 (USD Million)
• 4.6. Stimulants
  • 4.6.1. Stimulants Market, 2021 - 2033 (USD Million)
• 4.7. Sleep Medications
  • 4.7.1. Sleep Medications Market, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Autism Spectrum Disorder Treatment Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Autistic Disorder
  • 5.4.1. Autistic Disorder Market, 2021 - 2033 (USD Million)
• 5.5. Asperger Syndrome
  • 5.5.1. Asperger Syndrome Market, 2021 - 2033 (USD Million)
• 5.6. Pervasive Developmental Disorder
  • 5.6.1. Pervasive Developmental Disorder Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Autism Spectrum Disorder Treatment Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2033
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
• 6.4. Hospital Pharmacy
  • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
• 6.5. Retail Pharmacy
  • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
• 6.6. Online Pharmacy
  • 6.6.1. Online Pharmacy Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Johnson & Johnson (Janssen)
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Roche (F. Hoffmann-La Roche)
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Otsuka Pharmaceutical Co., Ltd.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. AbbVie Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Novartis AG
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Eli Lilly & Company
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Curemark LLC
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Yamo Pharmaceuticals
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. PaxMedica
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Merck & Co., Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 US autism spectrum disorder treatment market, by treatment type, 2021 - 2033 (USD Million)
• Table 4 US autism spectrum disorder treatment market, by application, 2021 - 2033 (USD Million)
• Table 5 US autism spectrum disorder treatment market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. autism spectrum disorder treatment market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Competitive landscape
• Fig. 10 U.S. autism spectrum disorder treatment market dynamics
• Fig. 11 U.S. autism spectrum disorder treatment market: Porter's five forces analysis
• Fig. 12 U.S. autism spectrum disorder treatment market: PESTLE analysis
• Fig. 13 Treatment Type market, 2021 - 2033 (USD Million)
• Fig. 14 Antipsychotic Drugs market, 2021 - 2033 (USD Million)
• Fig. 15 Selective Serotonin Reuptake Inhibitors market, 2021 - 2033 (USD Million)
• Fig. 16 Stimulants market, 2021 - 2033 (USD Million)
• Fig. 17 Sleep Medications market, 2021 - 2033 (USD Million)
• Fig. 18 Others market, 2021 - 2033 (USD Million)
• Fig. 19 Application market, 2021 - 2033 (USD Million)
• Fig. 20 Autistic Disorder market, 2021 - 2033 (USD Million)
• Fig. 21 Asperger Syndrome market, 2021 - 2033 (USD Million)
• Fig. 22 Pervasive Developmental Disorder market, 2021 - 2033 (USD Million)
• Fig. 23 Others market, 2021 - 2033 (USD Million)
• Fig. 24 Distribution Channel market, 2021 - 2033 (USD Million)
• Fig. 25 Hospital Pharmacy market, 2021 - 2033 (USD Million)
• Fig. 26 Retail Pharmacy market, 2021 - 2033 (USD Million)
• Fig. 27 Online Pharmacy market, 2021 - 2033 (USD Million)
• Fig. 28 Company categorization
• Fig. 29 Company market position analysis
• Fig. 30 Strategic framework